Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
31 janv. 2024 08h00 HE
|
Phio Pharmaceuticals Corp.
--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
RNA-based Therapeutics Market Outlook Report, 2023-2034: Personalized Medicine Adoption, Investment Inflows, and Pharma Collaborations Fueling Global Industry Growth
24 janv. 2024 14h22 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global RNA-based Therapeutics Market" report has been added to ResearchAndMarkets.com's offering. The Global RNA-based Therapeutics Market was...
RNAi Therapeutics Market Global Industry Analysis and Forecasts to 2030: A $20.23 Billion Market in 2030, with a CAGR of a 7.69% During 2023-2030
17 janv. 2024 12h03 HE
|
Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added to ResearchAndMarkets.com's...
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
08 janv. 2024 08h00 HE
|
Wave Life Sciences USA, Inc.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
07 déc. 2023 08h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
17 nov. 2023 08h00 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
09 nov. 2023 16h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
09 nov. 2023 07h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
03 nov. 2023 12h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
12 oct. 2023 11h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...